Gene Therapy for Bone Regeneration
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Efficacious bone regeneration could revolutionize the clinical management of many bone and musculoskeletal disorders. Bone has the unique ability to regenerate and continuously remodel itself throughout life. However, clinical situations arise when bone is unable to heal itself, as with segmental bone loss, fracture non-union, and failed spinal fusion. This leads to significant morbidity and mortality. Current attempts at improved bone healing have been met with limited success, fueling the development of improved techniques. Gene therapy in many ways represents an ideal approach for augmenting bone regeneration. Gene therapy allows specific gene products to be delivered to a precise anatomic location. In addition, the level of transgene expression as well as the duration of expression can be regulated with current techniques. For bone regeneration, the gene of interest should be delivered to the fracture site, expressed at appropriate levels, and then deactivated once the fracture has healed. Delivery of biological factors, mostly bone morphogenetic proteins (BMPs), has yielded promising results both in animal and clinical studies. There has also been tremendous work on discovering new growth factors and exploring previously defined ones. Finally, significant advances are being made in the delivery systems of the genes, ranging from viral and non-viral vectors to tissue engineering scaffolds. Despite some public hesitation to gene therapy, its use has great potential to expand our ability to treat a variety of human bone and musculoskeletal disorders. It is conceivable that in the near future gene therapy can be utilized to induce bone formation in virtually any region of the body in a minimally invasive manner. As bone biology and gene therapy research progresses, the goal of successful human gene transfer for augmentation of bone regeneration draws nearer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501 · cited 6×
“Five major types of viral vectors can be divided into two groups based on whether their genomes persist in a non-integrated form (i.e., adenovirus and herpes virus) or become integrated into host chromosomes (i.e., retrovirus, adeno-associated virus, and lentivirus) [Thomas et al., 2003].”
BackgroundInfluentialA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“In the second case, 2 of 11 patients treated successfully for severe combined immunodeficiency (SCID) developed a leukemia-like disorder apparently caused by retroviral genome integration causing a disruption in the oncogene LMO2 [Cavazzana-Calvo et al., 2000; Hacein-Bey-Abina et al., 2003].”
BackgroundGOVENDER, S., CSIMMA, C., GENANT, H. K., & VALENTIN-OPRAN, A. (2002) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/00004623-200212000-00001 · Cited by 1,308
Asakura, A., Rudnicki, M. A., & Komaki, M. (2001) · Differentiation · doi:10.1046/j.1432-0436.2001.680412.x · Cited by 839
Growth factors for bone growth and repair: IGF, TGFβ and BMP
Linkhart, T. A., Mohan, S., & Baylink, D. J. (1996) · Bone · doi:10.1016/s8756-3282(96)00138-x · Cited by 440 · cited 2×
“…FGFs [Aubin et al., 1995; Canalis et al., 1988; de Crombrugghe et al., 2001; Nakamura et al., 1998], IGF-1 and IGF-2 [Deasy et al., 2002; Gazzerro et al., 1998; Linkhart et al., 1996], TGF-β [Cheifetz et al., 1996], VEGF [Tarkka et al., 2003; Uchida et al., 2003] and BMPs [Seeherman et al., 2002].”
Background
Cited by
Liao, J., Wei, Q., Zou, Y., Fan, J., Song, D., Cui, J., Zhang, W., Zhu, Y., Ma, C., Hu, X., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000471945 · Cited by 2,742
Self-citationLee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
Self-citationLuu, H. H., Song, W., Luo, X., Manning, D., Luo, J., Deng, Z., Sharff, K. A., Montag, A. G., Haydon, R. C., & He, T. (2007) · Journal of Orthopaedic Research · doi:10.1002/jor.20359 · Cited by 545
Self-citationTissue engineering of bone: the reconstructive surgeon's point of view
Kneser, U., Schaefer, D. J., Polykandriotis, E., & Horch, R. E. (2006) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2006.tb00287.x · Cited by 509
Kang, Q., Song, W.-X., Luo, Q., Tang, N., Luo, J., Luo, X., Chen, J., Bi, Y., He, B.-C., Park, J. K., et al. (2009) · Stem Cells and Development · doi:10.1089/scd.2008.0130 · Cited by 382
Self-citation
Metadata
- Authors
- Luo, J., Sun, M., Kang, Q., Peng, Y., Jiang, W., Luu, H., Luo, Q., Park, J., Li, Y., & Haydon, R.
- Venue
- Current Gene Therapy
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-04-01
- Volume
- 5
- Issue
- 2
- Pages
- 167-179
- ISSN
- 1566-5232 (ISSN-L)
- OpenAlex
- W1963564766
- Cited by
- 101
- References
- 6
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene Therapy for Bone Regeneration. https://app.cochat.ai/papers/10.2174/1566523053544218
- The paper
- Luo, J., Sun, M., Kang, Q., Peng, Y., Jiang, W., Luu, H., Luo, Q., Park, J., Li, Y., & Haydon, R. (2005). Gene Therapy for Bone Regeneration. Current Gene Therapy. https://doi.org/10.2174/1566523053544218
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.